Compare Abeona Therapeutics Inc (ABEO) vs CF Industries Holdings, Inc. (CF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs CF Industries Holdings, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while CF Industries Holdings, Inc. trades at $117.3 (market cap $17.66B). The key difference: CF Industries Holdings, Inc. is far larger — about 47.3× Abeona Therapeutics Inc's market cap, and CF Industries Holdings, Inc. pays a 1.74% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CF | |
|---|---|---|
Market Cap | $373.32M | $17.66B |
Sector | Health | Basic Materials |
52-Week High | $7.23 | $137.55 |
52-Week Low | $4.17 | $76.08 |
Enterprise Value | $228.22M | $19.24B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
CF Industries stock trades at $114.92, up 3.96% today, with a bullish technical signal and strong fundamental metrics including a P/E of 10.2 and net income margin of 23.73%. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $5.71. Recent news highlights robust nitrogen demand and cash flow strength, though rising natural gas costs pose margin pressure.
The outlook remains positive given favorable analyst sentiment, with a consensus price target of $126.67 and 51% buy ratings. Key risks include input cost volatility and geopolitical factors affecting fertilizer markets, but the company's low-cost position and solid balance sheet support continued shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About CF Industries Holdings, Inc.
CF Industries is a leading producer and distributor of nitrogen fertilizers. The company operates seven nitrogen facilities in North America and holds joint venture interests in further production capacity in the United Kingdom and Trinidad and Tobago. CF makes nitrogen primarily using low-cost U.S. natural gas as its feedstock, making CF one of the lowest-cost nitrogen producers globally.
Read more on CF →
